In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital.Novavax President and CEO Stanley Erck said in an statement that the company plans to conduct Phase 3 clinical trials of NVX-Cov2373, its vaccine candidate, and deliver up to 100 million doses by the end of this year.